stockrow
Friday 6 November 2026
Export ALVO’s income statement to Excel — free account
Alvotech
ALVO Healthcare Drug Manufacturers Specialty & Generic
Alvotech’s revenue for fiscal 2025 (year ended December 2025) was $586.3 million, up 19.7% from fiscal 2024.
- Revenue
- +2,311.0%
- EPS
- −99.5%
- Free cash flow
- −496.6%
- Total debt
- +16.8%
Quarter to June 2026, against a year earlier
4.58
0.09
−1.93%
Follow ALVO
Alert me
Alvotech (ALVO) P/E ratio
Alvotech has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 13.3× (June 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| 5 more quarters | Free account |
Against its own ten years
Low 0.0×
High 13.3×
Ten-year median
0.0×
Current reading's percentile
83
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| XERS Xeris Biopharma Holdings, Inc. compare | n/m |
| PRGO Perrigo Company plc compare | n/m |
| BCRX BioCryst Pharmaceuticals, Inc. compare | n/m |
| ALVO Alvotech | n/m |
| TRLV Trulieve Cannabis Corp. compare | n/m |
| ANIP ANI Pharmaceuticals, Inc. compare | 13.3× |
| PAHC Phibro Animal Health Corporation compare | 14.0× |
| ETON Eton Pharmaceuticals, Inc. compare | 26.8× |
| PCRX Pacira BioSciences, Inc. compare | 38.4× |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)